Company profile

ADMA BIOLOGICS, INC.

NASDAQ:ADMABiotechnology: Biological Products (No Diagnostic Substances)

Drug pipeline (4)

Asset	Stage	Revenue	Trials	Status
ASCENIV	approved	$102.9MQ2 2026	0	—
BIVIGAM	approved	$19.4MQ2 2026	0	—
NABI-HB	approved	—	0	—
RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN)	phase3	—	1	no active trials

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (6)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT05070455	phase4	unknown	2022-09-01	2023-03-31	ADMA Biologics, Inc.	An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)
NCT00538915	phase3	completed	2007-09-01	2009-07-01	ADMA Biologics, Inc.	Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
NCT01814800	phase3	completed	2014-02-01	2014-12-01	ADMA Biologics, Inc.	Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
NCT00632463	phase2	completed	2008-02-01	2010-05-01	ADMA Biologics, Inc.	RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness
NCT00473824	phase2	terminated	2007-05-01	2009-02-01	ADMA Biologics, Inc.	Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

FDA applications (3)

Application

Approved

Type

Applicant

Products

BLA 125590

2019-04-01

BLA

ADMA BIOLOGICS, INC.

BLA 125389

2012-12-19

BLA

ADMA BIOLOGICS, INC.

BLA 103945

2001-10-23

BLA

ADMA BIOLOGICS, INC.